THESEUS PHARMACEUTICALS, INC. Net Income
THESEUS PHARMACEUTICALS, INC. reported Net Income of -$13.50 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2023-11-17
- THESEUS PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2023-09-30 was -$13.50M.
- THESEUS PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2023-06-30 was -$14.80M.
- THESEUS PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2023-03-31 was -$14.59M.
- THESEUS PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2022-12-31 was -$13.72M.
- THESEUS PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2022 was -$50.61M.
- THESEUS PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2021 was -$27.31M.
- THESEUS PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2020 was -$12.00M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$13.50M 10-Q · filed 2023-11-17 | -$28.31M derived: sum of 2 quarters · filed 2023-11-17 | -$42.90M 10-Q · filed 2023-11-17 | -$56.61M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | -$14.80M 10-Q · filed 2023-11-17 | -$29.39M 10-Q · filed 2023-08-10 | -$43.11M derived: sum of 3 quarters · filed 2023-11-17 | -$57.85M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-03-31 | -$14.59M 10-Q · filed 2023-11-17 | -$28.30M derived: sum of 2 quarters · filed 2023-11-17 | -$43.05M derived: sum of 3 quarters · filed 2023-11-17 | -$54.70M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-12-31 | -$13.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$28.46M derived: sum of 2 quarters · filed 2023-11-17 | -$40.11M derived: sum of 3 quarters · filed 2023-11-17 | -$50.61M 10-K · filed 2023-03-09 |
| 2022-09-30 | -$14.74M 10-Q · filed 2023-11-17 | -$26.39M derived: sum of 2 quarters · filed 2023-11-17 | -$36.89M 10-Q · filed 2023-11-17 | -$45.55M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | -$11.65M 10-Q · filed 2023-11-17 | -$22.15M 10-Q · filed 2023-08-10 | -$30.80M derived: sum of 3 quarters · filed 2023-11-17 | -$38.17M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-03-31 | -$10.50M 10-Q · filed 2023-11-17 | -$19.15M derived: sum of 2 quarters · filed 2023-11-17 | -$26.52M derived: sum of 3 quarters · filed 2023-11-17 | -$33.33M derived: sum of 4 quarters · filed 2023-11-17 |
| 2021-12-31 | -$8.66M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$16.03M derived: sum of 2 quarters · filed 2023-03-09 | -$22.84M derived: sum of 3 quarters · filed 2023-03-09 | -$27.31M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$7.37M 10-Q · filed 2022-11-03 | -$14.18M derived: sum of 2 quarters · filed 2022-11-03 | -$18.65M 10-Q · filed 2022-11-03 | -$21.54M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$6.81M 10-Q · filed 2022-11-03 | -$11.28M 10-Q · filed 2022-08-11 | -$14.17M derived: sum of 3 quarters · filed 2022-11-03 | -$15.60M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-03-31 | -$4.47M 10-Q · filed 2022-11-03 | -$7.36M derived: sum of 2 quarters · filed 2022-11-03 | -$8.79M derived: sum of 3 quarters · filed 2022-11-03 | -$14.21M derived: sum of 4 quarters · filed 2022-11-03 |
| 2020-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$4.32M derived: sum of 2 quarters · filed 2022-03-10 | -$9.73M derived: sum of 3 quarters · filed 2022-03-10 | -$12.00M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$1.43M 10-Q · filed 2021-11-15 | -$6.84M derived: sum of 2 quarters · filed 2021-11-15 | -$9.11M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$5.41M 10-Q · filed 2021-11-15 | -$7.68M derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | -$2.27M 10-Q · filed 2021-11-15 |